Accelerated Enrollment Solutions (AES), a business of PPD, Inc. (PPD), has launched a program to help biopharmaceutical companies maintain business continuity during the global COVID-19 pandemic by transferring clinical trial patients to AES’ dedicated research sites from other research facilities impacted by the coronavirus crisis.
As academic and hospital-based sites turn their attention to the front-line care of COVID-19 patients, and as independent sites experience diminished operating capacity related to COVID-19 concerns, biopharmaceutical companies face the prospect of delaying or canceling clinical trials of a wide variety of potential new medicines and ending patient participation in those trials. AES’ patient-transfer program is designed to address this issue through its global site organization, which includes dedicated research sites committed exclusively to clinical research.
“The transfer of patients to AES physical and virtual sites supports ongoing patient participation and allows for the continued collection of data for important trials supporting potentially life-changing therapies that aren’t necessarily connected to COVID-19,” said Roger Smith, general manager of AES. “As staff members from other sites are being called to support COVID-19 endeavors, this is a way for us to help their trial patients and support clinical research continuity, in addition to our organization’s ongoing work with our customers’ COVID-19 research. There is precedent for these transfers during normal operating conditions, and we believe the current pandemic will dramatically accelerate the need for solutions to support patients who are currently receiving investigational products and wish to maintain their participation status.”
With more than 180 research locations in 17 countries, AES has a broad global footprint that can support the transfer of patients, which ultimately depends on the sites’ proximity to the patients and their ability to support the trial protocol.
AES sites are operating under governments’ essential-business provisions and following official public health recommendations, including from the World Health Organization and the U.S. Centers for Disease Control and Prevention. In addition, AES is following COVID-19-related guidance from the U.S. Food and Drug Administration and European Medicines Agency to accommodate the transfer of patients between study sites.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.